💙 🔷 Not impressed by Big Tech in Q3? Explore these Blue Chip Bargains insteadExplore for free

Asahi Kasei Medical and AW Technologies enter exclusive distribution agreement for TrachFlush in Japan

Published 2024-04-03, 08:42 a/m
3407
-

TOKYO & NEW YORK & DÃœSSELDORF, Germany--(BUSINESS WIRE)--AW Technologies and Asahi Kasei Medical, a core operating company of the Asahi Kasei Group, have entered into an exclusive distribution agreement in Japan for AW Technologies' TrachFlush™ device. AW Technologies is currently in the process of medical device registration of the TrachFlush in Japan, with market launch targeted in fiscal 2024.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240403877269/en/

The TrachFlush and a unique cuff pressure control aligned with ventilator flow. (Graphic: Business Wire)

Developed by AW Technologies based on an invention by an intensivist, the TrachFlush is a medical device to reduce the discomfort of ventilated patients while lightening the workload on healthcare professionals during tracheal suctioning. The TrachFlush supports airway secretion (phlegm) management with a unique cuff pressure control system, and has received the CE Mark in Europe in 2020 and FDA clearance in the United States in 2023. In Japan, marketing and sale is to be performed by Asahi Kasei Medical.

With the push of a button, the TrachFlush deflates the cuff and utilizes the ventilator air pressure during an inspiratory cycle, and re-inflates the cuff before the cycle completes.

Ken Shinomiya, President of Asahi Kasei Medical, stated, "We are delighted to add the TrachFlush to our product lineup in the intensive care field, where we have strength in the area of blood purification. By leveraging our experience and know-how in blood purification, we believe that this will deliver diverse value, such as enhancing patients' QOL and reducing the burden on healthcare workers."

Adam Hansen, CEO of AW Technologies, commented, "We are very pleased and excited to announce our partnership with Asahi Kasei Medical. This partnership is very important for AW Technologies, and Asahi Kasei Medical will play a very important role in our expansion of TrachFlush globally. We believe the TrachFlush will have a great impact in the ICU “ not only by preventing ventilator-associated pneumonia, but also by non-invasively preventing the accumulation of secretion in the airways."

About AW Technologies ApS

AW Technologies is a Danish medical device company, established in 2018, focused on developing disruptive and innovative airway management solutions for mechanically ventilated patients in the ICU, including TrachFlush. For further information, please visit www.trachflush.com and www.awtechnologies.dk.

About Asahi Kasei and Asahi Kasei Medical

The Asahi Kasei Group contributes to life and living for people around the world. Since its foundation in 1922 with ammonia and cellulose fiber business, Asahi Kasei has consistently grown through the proactive transformation of its business portfolio to meet the evolving needs of every age. With more than 48,000 employees worldwide, the company contributes to sustainable society by providing solutions to the world's challenges through its three business sectors of Material, Homes, and Health Care. Asahi Kasei Medical is a core operating company in the Health Care sector. Its blood purification business comprises devices and systems for dialysis and therapeutic apheresis, and its bioprocess business comprises equipment for the manufacture of biotherapeutics, biosafety testing services, and biologics CDMO operations. For more information, visit www.asahi-kasei.com and www.asahi-kasei.co.jp/medical/en/.

North America Contact:
Asahi Kasei America Inc.
Christian OKeefe
christian.okeefe@ak-america.com

Europe Contact:
Asahi Kasei Europe GmbH
Sebastian Schmidt
sebastian.schmidt@asahi-kasei.eu

Source: Asahi Kasei Medical Co., Ltd.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.